PubRank

Emiliano Duranti

Author PubWeight™ 28.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension 2013 2.82
2 Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation 2009 1.49
3 Effect of mild hyperisulinemia on conduit vessel endothelial function: role of noradrenergic activation. J Hypertens 2012 1.42
4 Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway. Hypertension 2008 1.39
5 Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol 2011 1.16
6 Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension 2006 1.02
7 Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther 2007 1.01
8 Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II. Int J Hypertens 2011 0.96
9 Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 2009 0.96
10 Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006 0.95
11 The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. J Pharmacol Exp Ther 2010 0.93
12 Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors. J Hypertens 2013 0.90
13 Adipocytokine levels mark endothelial function in normotensive individuals. Cardiovasc Diabetol 2012 0.88
14 Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2004 0.88
15 Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. J Renin Angiotensin Aldosterone Syst 2013 0.86
16 Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 2010 0.85
17 Significant endothelin release in patients treated with foam sclerotherapy. Dermatol Surg 2012 0.83
18 Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats. Endocrinology 2008 0.82
19 Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012 0.82
20 Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. Int J Colorectal Dis 2013 0.82
21 Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment. PLoS One 2013 0.80
22 Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. Eur Heart J 2011 0.79
23 Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomed Pharmacother 2009 0.78
24 Vascular reactivity in patients with undifferentiated connective tissue diseases. Atherosclerosis 2008 0.77
25 P2X7 receptor polymorphisms do not influence endothelial function and vascular tone in neo-diagnosed, treatment-naive essential hypertensive patients. J Hypertens 2013 0.77
26 Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. Br J Pharmacol 2013 0.77
27 Haptoglobin deficiency determines changes in adipocyte size and adipogenesis. Adipocyte 2012 0.77
28 Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des 2013 0.77
29 Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction? Hypertension 2013 0.75
30 Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. J Hypertens 2016 0.75